Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

PHASE3CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

October 23, 2022

Primary Completion Date

September 15, 2023

Study Completion Date

April 2, 2024

Conditions
Blepharitis
Interventions
DRUG

Lotilaner

Lotilaner Ophthalmic Solution

DRUG

Vehicle Control

Vehicle of TP-03 ophthalmic solution

Trial Locations (21)

100005

Beijing Tongren Hospital, Beijing

100191

Peking University Third Hospital, Beijing

150007

The First Affiliated Hospital of Harbin Medical University, Harbin

200031

Eye& Ent Hospital of Fudan University, Shanghai

200940

Shanghai General Hospital, Shanghai

214002

Wuxi Second People's Hospital, Wuxi

300392

Tianjin Medical University Eye Hospital, Tianjin

310003

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

325027

Eye Hospital, Wenzhou Medical University, Wenzhou

361000

Xiamen Eye Center of Xiamen University, Xiamen

400020

Chongqing Aier Eye Hospital, Chongqing

410007

The Second Xiangya Hospital of Central South University, Changsha

410008

Xiangya Hospital, Central South University, Changsha

421001

The First Affiliated Hospital of University of South China, Hengyang

430022

Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

450008

Henan Provincial Eye Hospital, Zhengzhou

510040

Guangzhou Aier Eye Hospital, Guangzhou

510060

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou

570311

Hainan Eye Hospital, Haikou

030002

Shanxi Provincial Eye Hospital, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LianBio LLC

INDUSTRY